ID

37387

Beschrijving

Evaluation of CYP450 Activities in Diabetic Patients vs. Non-diabetic Subjects; ODM derived from: https://clinicaltrials.gov/show/NCT02291666

Link

https://clinicaltrials.gov/show/NCT02291666

Trefwoorden

Versies (1)
  1. 22-07-19 22-07-19 -
Houder van rechten

See clinicaltrials.gov

Geüploaded op

22 juli 2019

DOI

Voor een aanvraag inloggen.

Licentie

Creative Commons BY 4.0
Model Commentaren :

Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.

Terug naar het model Commentaren
Itemgroep Commentaren voor :

Item Commentaren voor :

U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.

Eligibility Type 2 Diabetes NCT02291666

Engels

Eligibility Type 2 Diabetes NCT02291666

1 Formulieren  
Inclusion Criteria
Beschrijving

Inclusion Criteria

Alias
UMLS CUI
C1512693
participants will be ≥18 years old
Beschrijving

Age

Datatype

boolean

Alias
UMLS CUI [1]
C0001779
body weight index ≤35,
Beschrijving

Body mass index

Datatype

boolean

Alias
UMLS CUI [1]
C1305855
non-smokers (>3 months)
Beschrijving

Non-smoker

Datatype

boolean

Alias
UMLS CUI [1]
C0337672
patients with type 2 diabetes and good glycemic control (a1c<7) or poor glycemic control (a1c>7.5) and healthy non-diabetic subjects will be elligible.
Beschrijving

Diabetes Mellitus, Non-Insulin-Dependent | Glycaemia control Good | Hemoglobin A1c measurement | Poor glycemic control | Healthy Volunteers

Datatype

boolean

Alias
UMLS CUI [1]
C0011860
UMLS CUI [2,1]
C3267174
UMLS CUI [2,2]
C0205170
UMLS CUI [3]
C0474680
UMLS CUI [4]
C0342299
UMLS CUI [5]
C1708335
Exclusion Criteria
Beschrijving

Exclusion Criteria

Alias
UMLS CUI
C0680251
subjects with estimated glomerular filtration (mdrd) <50ml/min/1.73m2
Beschrijving

GFR estimation by MDRD

Datatype

boolean

Alias
UMLS CUI [1]
C2170215
alt and ast 3 times above the upper limit of normal
Beschrijving

Alanine aminotransferase increased | Aspartate aminotransferase increased

Datatype

boolean

Alias
UMLS CUI [1]
C0151905
UMLS CUI [2]
C0151904
organ transplant recipient, inflammatory illnesses (i.e., polyarthritis, severe cirrhosis, infectious diseases)
Beschrijving

Transplanted organ Recipient | Inflammatory disorder | Polyarthritis | Liver Cirrhosis Severe | Communicable Diseases

Datatype

boolean

Alias
UMLS CUI [1,1]
C0524930
UMLS CUI [1,2]
C1709854
UMLS CUI [2]
C1290884
UMLS CUI [3]
C0162323
UMLS CUI [4,1]
C0023890
UMLS CUI [4,2]
C0205082
UMLS CUI [5]
C0009450
previous history of or an active cancer (except non-melanoma skin cancer)
Beschrijving

Malignant Neoplasms | Exception Skin carcinoma

Datatype

boolean

Alias
UMLS CUI [1]
C0006826
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C0699893
uncontrolled thyroid functions
Beschrijving

Thyroid function Uncontrolled

Datatype

boolean

Alias
UMLS CUI [1,1]
C2242456
UMLS CUI [1,2]
C0205318
pregnant
Beschrijving

Pregnancy

Datatype

boolean

Alias
UMLS CUI [1]
C0032961
history of drug or alcohol abuse
Beschrijving

Substance Use Disorders

Datatype

boolean

Alias
UMLS CUI [1]
C0038586
subjects with a history of or current inflammatory bowel diseases including ulcerous colitis and crohn's disease, and bariatric surgery
Beschrijving

Inflammatory Bowel Diseases | Ulcerative Colitis | Crohn Disease | Bariatric Surgery

Datatype

boolean

Alias
UMLS CUI [1]
C0021390
UMLS CUI [2]
C0009324
UMLS CUI [3]
C0010346
UMLS CUI [4]
C1456587
drugs known to modulate cyp450 activities, subject taking one of the following therapies will be excluded: antibiotics, antivirals, anticancers, cyp450 inducers (carbamazepine, phenobarbital, phenytoin, rifampin, st-john's wort), cyp450 inhibitors (amiodarone, fluvoxamine, fluoxetine, verapamil), immunosuppressors, warfarin, infs, antibodies or grapefruit juice (<4 weeks) or an investigational drug
Beschrijving

Pharmaceutical Preparations Modulating CYP450 Activity | Antibiotics | Antiviral Agents | Antineoplastic Agents | CYP450 Inducers | Carbamazepine | Phenobarbital | Phenytoin | Rifampin | ST. JOHN'S WORT EXTRACT | CYP450 Inhibitors | Amiodarone | Fluvoxamine | Fluoxetine | Verapamil | Immunosuppressive Agents | Warfarin | Interferons | Antibodies | Grapefruit juice | Investigational New Drugs

Datatype

boolean

Alias
UMLS CUI [1,1]
C0013227
UMLS CUI [1,2]
C0443264
UMLS CUI [1,3]
C0010762
UMLS CUI [1,4]
C0205177
UMLS CUI [2]
C0003232
UMLS CUI [3]
C0003451
UMLS CUI [4]
C0003392
UMLS CUI [5]
C3500477
UMLS CUI [6]
C0006949
UMLS CUI [7]
C0031412
UMLS CUI [8]
C0031507
UMLS CUI [9]
C0035608
UMLS CUI [10]
C0813171
UMLS CUI [11]
C2962191
UMLS CUI [12]
C0002598
UMLS CUI [13]
C0085228
UMLS CUI [14]
C0016365
UMLS CUI [15]
C0042523
UMLS CUI [16]
C0021081
UMLS CUI [17]
C0043031
UMLS CUI [18]
C0021747
UMLS CUI [19]
C0003241
UMLS CUI [20]
C0452456
UMLS CUI [21]
C0013230
intolerance or hypersensitivity to probe drugs in the crchum-mt cocktail or chlorzoxazone/acetaminophen
Beschrijving

Intolerance to Investigational New Drugs | Hypersensitivity Investigational New Drugs | Intolerance to Chlorzoxazone | CHLORZOXAZONE ALLERGY | Intolerance to Acetaminophen | Allergy to acetaminophen

Datatype

boolean

Alias
UMLS CUI [1,1]
C1744706
UMLS CUI [1,2]
C0013230
UMLS CUI [2,1]
C0020517
UMLS CUI [2,2]
C0013230
UMLS CUI [3,1]
C1744706
UMLS CUI [3,2]
C0008296
UMLS CUI [4]
C0742387
UMLS CUI [5,1]
C1744706
UMLS CUI [5,2]
C0000970
UMLS CUI [6]
C0570513
Terug naar het begin van de pagina

Similar models

Eligibility Type 2 Diabetes NCT02291666

1 Formulieren
Name
Type
Description | Question | Decode (Coded Value)
Datatype
Alias
Item Group
C1512693 (UMLS CUI)
Age
Item
participants will be ≥18 years old
boolean
C0001779 (UMLS CUI [1])
Body mass index
Item
body weight index ≤35,
boolean
C1305855 (UMLS CUI [1])
Non-smoker
Item
non-smokers (>3 months)
boolean
C0337672 (UMLS CUI [1])
Diabetes Mellitus, Non-Insulin-Dependent | Glycaemia control Good | Hemoglobin A1c measurement | Poor glycemic control | Healthy Volunteers
Item
patients with type 2 diabetes and good glycemic control (a1c<7) or poor glycemic control (a1c>7.5) and healthy non-diabetic subjects will be elligible.
boolean
C0011860 (UMLS CUI [1])
C3267174 (UMLS CUI [2,1])
C0205170 (UMLS CUI [2,2])
C0474680 (UMLS CUI [3])
C0342299 (UMLS CUI [4])
C1708335 (UMLS CUI [5])
Item Group
C0680251 (UMLS CUI)
GFR estimation by MDRD
Item
subjects with estimated glomerular filtration (mdrd) <50ml/min/1.73m2
boolean
C2170215 (UMLS CUI [1])
Alanine aminotransferase increased | Aspartate aminotransferase increased
Item
alt and ast 3 times above the upper limit of normal
boolean
C0151905 (UMLS CUI [1])
C0151904 (UMLS CUI [2])
Transplanted organ Recipient | Inflammatory disorder | Polyarthritis | Liver Cirrhosis Severe | Communicable Diseases
Item
organ transplant recipient, inflammatory illnesses (i.e., polyarthritis, severe cirrhosis, infectious diseases)
boolean
C0524930 (UMLS CUI [1,1])
C1709854 (UMLS CUI [1,2])
C1290884 (UMLS CUI [2])
C0162323 (UMLS CUI [3])
C0023890 (UMLS CUI [4,1])
C0205082 (UMLS CUI [4,2])
C0009450 (UMLS CUI [5])
Malignant Neoplasms | Exception Skin carcinoma
Item
previous history of or an active cancer (except non-melanoma skin cancer)
boolean
C0006826 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C0699893 (UMLS CUI [2,2])
Thyroid function Uncontrolled
Item
uncontrolled thyroid functions
boolean
C2242456 (UMLS CUI [1,1])
C0205318 (UMLS CUI [1,2])
Pregnancy
Item
pregnant
boolean
C0032961 (UMLS CUI [1])
Substance Use Disorders
Item
history of drug or alcohol abuse
boolean
C0038586 (UMLS CUI [1])
Inflammatory Bowel Diseases | Ulcerative Colitis | Crohn Disease | Bariatric Surgery
Item
subjects with a history of or current inflammatory bowel diseases including ulcerous colitis and crohn's disease, and bariatric surgery
boolean
C0021390 (UMLS CUI [1])
C0009324 (UMLS CUI [2])
C0010346 (UMLS CUI [3])
C1456587 (UMLS CUI [4])
Pharmaceutical Preparations Modulating CYP450 Activity | Antibiotics | Antiviral Agents | Antineoplastic Agents | CYP450 Inducers | Carbamazepine | Phenobarbital | Phenytoin | Rifampin | ST. JOHN'S WORT EXTRACT | CYP450 Inhibitors | Amiodarone | Fluvoxamine | Fluoxetine | Verapamil | Immunosuppressive Agents | Warfarin | Interferons | Antibodies | Grapefruit juice | Investigational New Drugs
Item
drugs known to modulate cyp450 activities, subject taking one of the following therapies will be excluded: antibiotics, antivirals, anticancers, cyp450 inducers (carbamazepine, phenobarbital, phenytoin, rifampin, st-john's wort), cyp450 inhibitors (amiodarone, fluvoxamine, fluoxetine, verapamil), immunosuppressors, warfarin, infs, antibodies or grapefruit juice (<4 weeks) or an investigational drug
boolean
C0013227 (UMLS CUI [1,1])
C0443264 (UMLS CUI [1,2])
C0010762 (UMLS CUI [1,3])
C0205177 (UMLS CUI [1,4])
C0003232 (UMLS CUI [2])
C0003451 (UMLS CUI [3])
C0003392 (UMLS CUI [4])
C3500477 (UMLS CUI [5])
C0006949 (UMLS CUI [6])
C0031412 (UMLS CUI [7])
C0031507 (UMLS CUI [8])
C0035608 (UMLS CUI [9])
C0813171 (UMLS CUI [10])
C2962191 (UMLS CUI [11])
C0002598 (UMLS CUI [12])
C0085228 (UMLS CUI [13])
C0016365 (UMLS CUI [14])
C0042523 (UMLS CUI [15])
C0021081 (UMLS CUI [16])
C0043031 (UMLS CUI [17])
C0021747 (UMLS CUI [18])
C0003241 (UMLS CUI [19])
C0452456 (UMLS CUI [20])
C0013230 (UMLS CUI [21])
Intolerance to Investigational New Drugs | Hypersensitivity Investigational New Drugs | Intolerance to Chlorzoxazone | CHLORZOXAZONE ALLERGY | Intolerance to Acetaminophen | Allergy to acetaminophen
Item
intolerance or hypersensitivity to probe drugs in the crchum-mt cocktail or chlorzoxazone/acetaminophen
boolean
C1744706 (UMLS CUI [1,1])
C0013230 (UMLS CUI [1,2])
C0020517 (UMLS CUI [2,1])
C0013230 (UMLS CUI [2,2])
C1744706 (UMLS CUI [3,1])
C0008296 (UMLS CUI [3,2])
C0742387 (UMLS CUI [4])
C1744706 (UMLS CUI [5,1])
C0000970 (UMLS CUI [5,2])
C0570513 (UMLS CUI [6])
Terug naar het begin van de pagina 

Contact

Gebruik dit formulier voor feedback, vragen en verbeteringsvoorstellen.

Velden gemarkeerd met een * zijn verplicht.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial